公司事件 - Altimmune因Pemvidutide治疗MASH的IMPACT Phase 2b试验未达到纤维化减少主要终点的统计学显著性而面临集体诉讼 [4] - 公司股价从2025年6月25日的7.71美元暴跌53.2%至6月26日的3.61美元 [5] - 诉讼指控公司在试验结果公布前持续夸大预期 但实际数据因安慰剂反应高于预期而失败 [4] 法律行动 - 律师事务所Faruqi & Faruqi正在调查Altimmune潜在证券索赔案件 并设定2025年10月6日为首席原告申请截止日 [2] - 该律所自1995年成立以来已为投资者追回数亿美元损失 [3] - 鼓励知情者提供Altimmune行为相关信息 包括举报人、前员工和股东 [7] 投资者影响 - 受影响投资者范围为2023年8月10日至2025年6月25日期间购入Altimmune证券的人士 [1] - 首席原告需为集体诉讼中财务利益最大且具代表性的投资者 [6] - 参与诉讼与否不影响未来可能的赔偿分配 [6]

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submi ...

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=159976&from=3 CLASS PERIOD: August 10, 2023 ...

LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 10, 2023 and June 25, 2025, inclusive (the "Class Period"), are e ...

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025. Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbi ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) investors of a class action representing investors that bought securities between August 10, 2023 and June 25, 2025, inclusive (the "Class Period"). Altimmune investors have until October 6, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. P ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options. If you suffered losses exceeding $75,000 in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 06, 2025 (GLOB ...

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all persons or entities who purchased the securities of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants provided overwhelmingly positive statements to investors wh ...

诉讼案件 - Altimmune公司因证券问题面临集体诉讼 案件编号为8:25-cv-02581 诉讼期间为2023年8月10日至2025年6月25日 [1] - 诉讼由Levi & Korsinsky律师事务所发起 该律所在过去20年中为股东追回数亿美元赔偿 并连续7年入选ISS证券集体诉讼服务Top 50报告 [5] 临床试验结果 - 2025年6月26日 Altimmune公布Pemvidutide治疗MASH的IMPACT 2b期试验顶线结果 未能达到纤维化减少主要终点的统计学显著性 [3] - 虽然观察到纤维化改善的积极趋势 但由于安慰剂组反应高于预期 导致结果未达统计学意义 [3] - 公司将此结果归因于2期试验性质 并表示期待3期试验获得更好结果 [3] 股价影响 - 消息公布后 Altimmune股价从2025年6月25日收盘价7.71美元暴跌至6月26日的3.61美元 单日跌幅达53.2% [4] - 投资者损失索赔截止日期为2025年10月6日 [4]

文章核心观点 Altimmune公司将于2025年6月26日上午8:30举办投资者网络直播，公布IMPACT 2b期试验评估pemvidutide治疗代谢功能障碍相关脂肪性肝炎（MASH）的24周顶线数据 [1] 会议信息 - 公司将于2025年6月26日上午8:30举办电话会议和网络直播，管理层和相关专家将发表讲话，会议结束后可在公司网站重播 [2] - 会议日期为2025年6月26日，时间为上午8:30，可通过公司投资者关系网站收听直播，需注册获取拨入号码和PIN码 [5] IMPACT研究 - IMPACT试验（NCT05989711）招募212名活检确诊的MASH和纤维化F2/F3期患者，随机1:2:2接受每周皮下注射1.2mg和1.8mg pemvidutide或安慰剂治疗24周，关键疗效终点为24周时MASH缓解或纤维化改善，次要终点包括体重减轻和非侵入性测试，患者将接受48周治疗，预计2025年第四季度有最终结果 [3] Pemvidutide药物 - Pemvidutide是一种新型研究性基于肽的1:1 GLP - 1/胰高血糖素双受体激动剂，用于治疗MASH、肥胖、酒精使用障碍（AUD）和酒精相关性肝病（ALD），激活受体可模拟饮食和运动对减肥的互补作用，在临床试验中显示出显著疗效，获美国FDA快速通道指定 [4] - 2024年完成MOMENTUM 2期肥胖试验，正在进行IMPACT 2b期MASH试验，AUD和ALD的IND申请获FDA批准，AUD的2期试验正在进行，ALD的2期试验计划于2025年第三季度开始 [4] 公司概况 - Altimmune是一家后期临床阶段生物制药公司，专注开发基于肽的肝脏和心脏代谢疾病疗法，主要项目是pemvidutide [5] 公司联系方式 - 公司首席财务官Greg Weaver，电话240 - 654 - 1450，邮箱ir@altimmune.com [7] - 投资者联系Lee Roth和Burns McClellan，电话646 - 382 - 3403，邮箱lroth@burnsmc.com [7] - 媒体联系Jake Robison，电话619 - 849 - 5383，邮箱jake.robison@inizioevoke.com [7]